# Pediatric Neurology
## A Comprehensive Guide for Medical Students

[![License: CC BY-NC-SA 4.0](https://img.shields.io/badge/License-CC%20BY--NC--SA%204.0-lightgrey.svg)](https://creativecommons.org/licenses/by-nc-sa/4.0/)

**Author: YK Shim**
**Division of Pediatric Neurology, Department of Pediatrics, Korea University College of Medicine**
**Last Updated: 2025**

---

## Table of Contents

1. [Introduction](#1-introduction)
2. [Seizure Fundamentals](#2-seizure-fundamentals)
3. [ILAE Classification of Epilepsy](#3-ilae-classification-of-epilepsy)
4. [Electroencephalography (EEG)](#4-electroencephalography-eeg)
5. [Seizures in the Genetic Era](#5-seizures-in-the-genetic-era)
6. [Medical Evaluation and Diagnostic Workup](#6-medical-evaluation-and-diagnostic-workup)
7. [Physical Examination and Phenotyping](#7-physical-examination-and-phenotyping)
8. [Precision Medicine in Epilepsy](#8-precision-medicine-in-epilepsy)
9. [Clinical Pearls and Pitfalls](#9-clinical-pearls-and-pitfalls)
10. [Summary: Approach to Pediatric Neurologic Diseases](#10-summary-approach-to-pediatric-neurologic-diseases)
11. [Learning Objectives and Self-Assessment](#11-learning-objectives-and-self-assessment)
12. [References and Further Reading](#12-references-and-further-reading)

---

## 1. Introduction

Pediatric neurology encompasses disorders of the nervous system in children, from neonates to adolescents. The developing brain presents unique challenges and opportunities for diagnosis and treatment.

### Why This Matters

```
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚                    PEDIATRIC EPILEPSY IMPACT                    â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚                                                                 â”‚
â”‚   ğŸ“Š PREVALENCE        ğŸ§  IMPACT           ğŸ¯ OPPORTUNITY       â”‚
â”‚   â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€        â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€          â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€        â”‚
â”‚   0.5-1% of            Affects             Early diagnosis      â”‚
â”‚   children             development         enables targeted     â”‚
â”‚   worldwide            & quality           therapy              â”‚
â”‚                        of life                                  â”‚
â”‚                                                                 â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
```

---

## 2. Seizure Fundamentals

### 2.1 Core Definitions

```
â•”â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•—
â•‘                           KEY DEFINITIONS                                      â•‘
â• â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•£
â•‘                                                                               â•‘
â•‘  SEIZURE                                                                      â•‘
â•‘  â•â•â•â•â•â•â•â•                                                                     â•‘
â•‘  Transient signs/symptoms due to abnormal excessive                           â•‘
â•‘  or synchronous neuronal activity in the brain                                â•‘
â•‘                                                                               â•‘
â•‘  EPILEPSY                                                                     â•‘
â•‘  â•â•â•â•â•â•â•â•                                                                     â•‘
â•‘  â‰¥2 unprovoked seizures >24h apart                                           â•‘
â•‘           OR                                                                  â•‘
â•‘  1 seizure + recurrence risk â‰¥60%                                            â•‘
â•‘                                                                               â•‘
â•‘  STATUS EPILEPTICUS                                                           â•‘
â•‘  â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•                                                           â•‘
â•‘  Seizure lasting >5 minutes OR multiple seizures                              â•‘
â•‘  without full recovery between them                                           â•‘
â•‘                                                                               â•‘
â•šâ•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•
```

### 2.2 Seizure Semiology: What to Observe

```
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚                        SEIZURE OBSERVATION TIMELINE                          â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚                                                                             â”‚
â”‚   PRE-ICTAL          ICTAL PHASE           POST-ICTAL                       â”‚
â”‚   â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€         â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€           â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€                       â”‚
â”‚                                                                             â”‚
â”‚   â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”       â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”         â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”                     â”‚
â”‚   â”‚ WARNING â”‚ â”€â”€â”€â–¶  â”‚  SEIZURE  â”‚  â”€â”€â”€â–¶   â”‚ RECOVERY â”‚                     â”‚
â”‚   â”‚ (Aura)  â”‚       â”‚  ACTIVITY â”‚         â”‚  PHASE   â”‚                     â”‚
â”‚   â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜       â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜         â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜                     â”‚
â”‚                                                                             â”‚
â”‚   â€¢ Behavior        â€¢ Where did it        â€¢ Confusion?                      â”‚
â”‚   â€¢ Activity          start?              â€¢ Weakness?                       â”‚
â”‚   â€¢ Triggers        â€¢ Progression?        â€¢ Duration?                       â”‚
â”‚                     â€¢ Awareness?          â€¢ Sleep?                          â”‚
â”‚                     â€¢ Duration?                                             â”‚
â”‚                                                                             â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
```

### 2.3 Seizure History Checklist

| Question | Why It Matters |
|----------|----------------|
| What was the patient doing before? | Identify triggers |
| Was there any warning (aura)? | Suggests focal onset |
| Where did movements start? | Localization |
| What was the sequence? | Seizure propagation |
| Was there loss of awareness? | Focal vs. generalized |
| How long did each phase last? | Severity assessment |
| What was the postictal state? | Todd's paralysis, confusion |
| Any triggers? | Fever, sleep deprivation, photic |

---

## 3. ILAE Classification of Epilepsy

### 3.1 Three Levels of Diagnosis (ILAE 2017)

<div class="mermaid">
flowchart TD
    A[ğŸ” LEVEL 1: SEIZURE TYPE] --> B[ğŸ“‹ LEVEL 2: EPILEPSY TYPE]
    B --> C[ğŸ¥ LEVEL 3: EPILEPSY SYNDROME]

    A --> A1[Focal]
    A --> A2[Generalized]
    A --> A3[Unknown]

    B --> B1[Focal Epilepsy]
    B --> B2[Generalized Epilepsy]
    B --> B3[Combined]
    B --> B4[Unknown]

    C --> C1[Specific Syndrome<br/>e.g., Dravet, CAE]

    style A fill:#e1f5fe
    style B fill:#fff3e0
    style C fill:#e8f5e9
</div>

### 3.2 Seizure Classification Overview (ILAE 2017/2025)

```
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚                        ILAE SEIZURE CLASSIFICATION                            â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚                                                                               â”‚
â”‚                              SEIZURE ONSET                                    â”‚
â”‚                    â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”                               â”‚
â”‚                    â–¼            â–¼            â–¼                               â”‚
â”‚              â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”  â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”  â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”                          â”‚
â”‚              â”‚  FOCAL  â”‚  â”‚GENERALIZEDâ”‚  â”‚ UNKNOWN â”‚                          â”‚
â”‚              â””â”€â”€â”€â”€â”¬â”€â”€â”€â”€â”˜  â””â”€â”€â”€â”€â”€â”¬â”€â”€â”€â”€â”˜  â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜                          â”‚
â”‚                   â”‚             â”‚                                             â”‚
â”‚         â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”´â”€â”€â”€â”€â”€â”€â”€â”€â”    â”‚                                             â”‚
â”‚         â–¼                 â–¼    â–¼                                             â”‚
â”‚    â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”      â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”                      â”‚
â”‚    â”‚AWARENESSâ”‚      â”‚           MOTOR                 â”‚                      â”‚
â”‚    â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤      â”‚  â€¢ Tonic-clonic  â€¢ Myoclonic   â”‚                      â”‚
â”‚    â”‚Retained â”‚      â”‚  â€¢ Tonic         â€¢ Atonic      â”‚                      â”‚
â”‚    â”‚Impaired â”‚      â”‚  â€¢ Clonic        â€¢ Spasms      â”‚                      â”‚
â”‚    â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜      â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜                      â”‚
â”‚         â”‚                                                                     â”‚
â”‚         â–¼           â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”                      â”‚
â”‚    â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”      â”‚         NON-MOTOR               â”‚                      â”‚
â”‚    â”‚  ONSET  â”‚      â”‚  â€¢ Typical absence              â”‚                      â”‚
â”‚    â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤      â”‚  â€¢ Atypical absence             â”‚                      â”‚
â”‚    â”‚Motor    â”‚      â”‚  â€¢ Myoclonic absence            â”‚                      â”‚
â”‚    â”‚Non-motorâ”‚      â”‚  â€¢ Eyelid myoclonia             â”‚                      â”‚
â”‚    â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜      â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜                      â”‚
â”‚                                                                               â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
```

### 3.3 Focal Seizure Features

| Feature | Options | Clinical Significance |
|---------|---------|----------------------|
| **Awareness** | Retained / Impaired | Replaces "simple" vs "complex" |
| **Motor Onset** | Automatisms, Atonic, Clonic, Tonic, Hyperkinetic, Myoclonic, Spasms | Helps localize |
| **Non-Motor Onset** | Autonomic, Behavior arrest, Cognitive, Emotional, Sensory | Suggests specific regions |
| **Progression** | Focal to bilateral tonic-clonic | Previously "secondary generalized" |

### 3.4 Epilepsy Syndromes by Age

```
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚                     EPILEPSY SYNDROMES BY AGE OF ONSET                          â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚                                                                                 â”‚
â”‚  NEONATES & INFANTS (0-2 years)                                                â”‚
â”‚  â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•                                               â”‚
â”‚  â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”   â”‚
â”‚  â”‚ â€¢ Self-limited neonatal epilepsy          ğŸŸ¢ Good prognosis            â”‚   â”‚
â”‚  â”‚ â€¢ Self-limited familial neonatal epilepsy ğŸŸ¢ Good prognosis            â”‚   â”‚
â”‚  â”‚ â€¢ Early infantile DEE (Ohtahara)          ğŸ”´ Severe                    â”‚   â”‚
â”‚  â”‚ â€¢ Epilepsy of infancy with migrating      ğŸ”´ Severe                    â”‚   â”‚
â”‚  â”‚   focal seizures (EIMFS)                                               â”‚   â”‚
â”‚  â”‚ â€¢ Infantile spasms (West syndrome)        ğŸŸ  Variable                  â”‚   â”‚
â”‚  â”‚ â€¢ Dravet syndrome                         ğŸ”´ Severe                    â”‚   â”‚
â”‚  â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜   â”‚
â”‚                                                                                 â”‚
â”‚  CHILDHOOD (2-12 years)                                                        â”‚
â”‚  â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•                                                       â”‚
â”‚  â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”   â”‚
â”‚  â”‚ Self-Limited Focal:                                                     â”‚   â”‚
â”‚  â”‚ â€¢ SLECTS (Rolandic)                       ğŸŸ¢ Excellent prognosis       â”‚   â”‚
â”‚  â”‚ â€¢ Panayiotopoulos syndrome                ğŸŸ¢ Excellent prognosis       â”‚   â”‚
â”‚  â”‚ â€¢ Childhood occipital visual epilepsy     ğŸŸ¢ Good prognosis            â”‚   â”‚
â”‚  â”‚                                                                         â”‚   â”‚
â”‚  â”‚ Generalized:                                                            â”‚   â”‚
â”‚  â”‚ â€¢ Childhood absence epilepsy (CAE)        ğŸŸ¢ Good (70% remission)      â”‚   â”‚
â”‚  â”‚ â€¢ Epilepsy with myoclonic absences        ğŸŸ  Variable                  â”‚   â”‚
â”‚  â”‚ â€¢ Epilepsy with eyelid myoclonia          ğŸŸ  Often lifelong            â”‚   â”‚
â”‚  â”‚                                                                         â”‚   â”‚
â”‚  â”‚ DEE:                                                                    â”‚   â”‚
â”‚  â”‚ â€¢ Lennox-Gastaut syndrome                 ğŸ”´ Severe, refractory        â”‚   â”‚
â”‚  â”‚ â€¢ ESES/CSWS                               ğŸŸ  Cognitive impact          â”‚   â”‚
â”‚  â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜   â”‚
â”‚                                                                                 â”‚
â”‚  ADOLESCENCE (12-18 years)                                                     â”‚
â”‚  â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•                                                     â”‚
â”‚  â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”   â”‚
â”‚  â”‚ â€¢ Juvenile absence epilepsy (JAE)         ğŸŸ  Often lifelong treatment  â”‚   â”‚
â”‚  â”‚ â€¢ Juvenile myoclonic epilepsy (JME)       ğŸŸ  Lifelong treatment needed â”‚   â”‚
â”‚  â”‚ â€¢ Epilepsy with GTC alone                 ğŸŸ  Variable                  â”‚   â”‚
â”‚  â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜   â”‚
â”‚                                                                                 â”‚
â”‚  Legend: ğŸŸ¢ Good/Excellent  ğŸŸ  Variable/Moderate  ğŸ”´ Severe/Poor               â”‚
â”‚                                                                                 â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
```

---

## 4. Electroencephalography (EEG)

### 4.1 EEG Electrode Placement (10-20 System)

```
                        INTERNATIONAL 10-20 SYSTEM
                        â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•

                              Nasion
                                â”‚
                    â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
                   Fp1         Fpz         Fp2
                    â”‚    â•²      â”‚      â•±    â”‚
                   F7â”€â”€â”€â”€F3â”€â”€â”€â”€Fzâ”€â”€â”€â”€F4â”€â”€â”€â”€F8
                    â”‚     â”‚     â”‚     â”‚     â”‚
                   T3â”€â”€â”€â”€C3â”€â”€â”€â”€Czâ”€â”€â”€â”€C4â”€â”€â”€â”€T4
                    â”‚     â”‚     â”‚     â”‚     â”‚
                   T5â”€â”€â”€â”€P3â”€â”€â”€â”€Pzâ”€â”€â”€â”€P4â”€â”€â”€â”€T6
                    â”‚    â•±      â”‚      â•²    â”‚
                   O1â”€â”€â”€â”€â”€â”€â”€â”€â”€Ozâ”€â”€â”€â”€â”€â”€â”€â”€â”€O2
                                â”‚
                              Inion

        â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
        â”‚  Fp = Frontopolar    F = Frontal            â”‚
        â”‚  T  = Temporal       C = Central            â”‚
        â”‚  P  = Parietal       O = Occipital          â”‚
        â”‚  z  = Midline        Odd = Left  Even = Rightâ”‚
        â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
```

### 4.2 Age-Dependent PDR Development

```
    POSTERIOR DOMINANT RHYTHM (PDR) MATURATION
    â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•

    Frequency (Hz)
         â”‚
      11 â”¤                                          â•â•â•â•â•â• Adult
      10 â”¤                                    â—â”â”â”â”â”â—
       9 â”¤                              â—â”â”â”â”â”â”˜
       8 â”¤                        â—â”â”â”â”â”â”˜
       7 â”¤                  â—â”â”â”â”â”â”˜
       6 â”¤            â—â”â”â”â”â”â”˜
       5 â”¤      â—â”â”â”â”â”â”˜
       4 â”¤â—â”â”â”â”â”â”˜
       3 â”¤
       2 â”¤
       1 â”¤
         â””â”€â”€â”¬â”€â”€â”€â”€â”€â”¬â”€â”€â”€â”€â”€â”¬â”€â”€â”€â”€â”€â”¬â”€â”€â”€â”€â”€â”¬â”€â”€â”€â”€â”€â”¬â”€â”€â”€â”€â”€â”¬â”€â”€â”€â”€â”€â”¬â”€â”€â–¶ Age
           3mo   6mo   1yr   2yr   3yr   5yr   8yr  10yr

    â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
    â”‚  CLINICAL PEARL: PDR should be at least [Age in years + 2]  â”‚
    â”‚  Example: 5-year-old should have PDR â‰¥ 7 Hz                 â”‚
    â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
```

### 4.3 Normal vs Abnormal EEG Patterns

```
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚                           EEG PATTERN RECOGNITION                               â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚                                                                                 â”‚
â”‚  âœ… NORMAL VARIANTS (Don't over-interpret!)                                     â”‚
â”‚  â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•                                   â”‚
â”‚                                                                                 â”‚
â”‚  Pattern                    Appearance           Age Range                      â”‚
â”‚  â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€                   â”‚
â”‚  Posterior slow of youth    âˆ¿âˆ¿âˆ¿ Delta waves     Children < 12 yrs              â”‚
â”‚                             posterior                                           â”‚
â”‚                                                                                 â”‚
â”‚  Mu rhythm                  âŒ’âŒ’âŒ’ Arch-shaped     Any age                        â”‚
â”‚                             8-10 Hz, central                                    â”‚
â”‚                                                                                 â”‚
â”‚  Lambda waves               âˆ§ Sharp             Visual scanning                 â”‚
â”‚                             occipital                                           â”‚
â”‚                                                                                 â”‚
â”‚  Hypnagogic hypersynchrony  â‰‹â‰‹â‰‹ High amp       Children                        â”‚
â”‚                             theta, drowsy                                       â”‚
â”‚                                                                                 â”‚
â”‚  POSTS                      â‹ Positive          Adolescents                     â”‚
â”‚                             occipital                                           â”‚
â”‚                                                                                 â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚                                                                                 â”‚
â”‚  âš ï¸ EPILEPTIFORM PATTERNS                                                       â”‚
â”‚  â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•                                                       â”‚
â”‚                                                                                 â”‚
â”‚  Pattern                    Appearance           Associated Syndrome            â”‚
â”‚  â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€           â”‚
â”‚  Centrotemporal spikes      â•±â•²                  SLECTS (Rolandic)              â”‚
â”‚                             C3/C4, T3/T4                                        â”‚
â”‚                                                                                 â”‚
â”‚  3 Hz spike-wave            â•±â•²_â•±â•²_â•±â•²           Childhood absence               â”‚
â”‚                             Generalized                                         â”‚
â”‚                                                                                 â”‚
â”‚  Hypsarrhythmia             â‰‹âˆ§â‰‹âˆ§â‰‹âˆ§             West syndrome                   â”‚
â”‚                             Chaotic, high amp                                   â”‚
â”‚                                                                                 â”‚
â”‚  Slow spike-wave (<2.5 Hz)  â•±â•²__â•±â•²__           Lennox-Gastaut                  â”‚
â”‚                             Generalized                                         â”‚
â”‚                                                                                 â”‚
â”‚  Polyspike-wave             â•±â•²â•±â•²â•±â•²_            JME                             â”‚
â”‚                             Multiple spikes                                     â”‚
â”‚                                                                                 â”‚
â”‚  Burst-suppression          âˆ§âˆ§âˆ§____âˆ§âˆ§âˆ§____     Early infantile DEE            â”‚
â”‚                             Bursts + flat                                       â”‚
â”‚                                                                                 â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
```

### 4.4 EEG Patterns and Associated Syndromes

| EEG Pattern | Visual | Syndrome | Key Features |
|-------------|--------|----------|--------------|
| **3 Hz Spike-Wave** | `âˆ§_âˆ§_âˆ§_` | Childhood Absence | Abrupt onset/offset, hyperventilation activates |
| **Centrotemporal Spikes** | `_âˆ§_` | SLECTS/Rolandic | Sleep-activated, horizontal dipole |
| **Hypsarrhythmia** | `â‰‹âˆ§â‰‹` | Infantile Spasms | Chaotic, asynchronous, high amplitude |
| **Slow Spike-Wave** | `âˆ§__âˆ§__` | Lennox-Gastaut | <2.5 Hz, runs during sleep |
| **Burst-Suppression** | `âˆ§âˆ§âˆ§___` | Early DEE | Bursts alternating with flat periods |
| **Photoparoxysmal** | `âˆ§âˆ§âˆ§` | JME, Dravet | Triggered by photic stimulation |

---

## 5. Seizures in the Genetic Era

### 5.1 Genetic Architecture of Epilepsy

```
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚              GENETIC ARCHITECTURE OF EPILEPSY                                   â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚                                                                                 â”‚
â”‚                            40% of epilepsies have                               â”‚
â”‚                          significant genetic component                          â”‚
â”‚                                                                                 â”‚
â”‚  EFFECT SIZE                                                                    â”‚
â”‚       â–²                                                                         â”‚
â”‚       â”‚    â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”     â”‚
â”‚  HIGH â”‚    â”‚  RARE VARIANTS                                              â”‚     â”‚
â”‚       â”‚    â”‚  â€¢ De novo mutations        ğŸ§¬ SCN1A, KCNQ2, STXBP1         â”‚     â”‚
â”‚       â”‚    â”‚  â€¢ Single gene disorders    ğŸ§¬ Found by WES/WGS             â”‚     â”‚
â”‚       â”‚    â”‚  â€¢ Large effect             ğŸ§¬ Often DEEs                   â”‚     â”‚
â”‚       â”‚    â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜     â”‚
â”‚       â”‚                                                                         â”‚
â”‚       â”‚              THE MISSING                                                â”‚
â”‚       â”‚              HERITABILITY                                               â”‚
â”‚       â”‚                  GAP                                                    â”‚
â”‚       â”‚                                                                         â”‚
â”‚       â”‚    â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”     â”‚
â”‚  LOW  â”‚    â”‚  COMMON VARIANTS                                            â”‚     â”‚
â”‚       â”‚    â”‚  â€¢ Found by GWAS            ğŸ§¬ Polygenic risk               â”‚     â”‚
â”‚       â”‚    â”‚  â€¢ Small individual effect  ğŸ§¬ IGE/GGE associations         â”‚     â”‚
â”‚       â”‚    â”‚  â€¢ Cumulative effect        ğŸ§¬ Population risk              â”‚     â”‚
â”‚       â”‚    â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜     â”‚
â”‚       â”‚                                                                         â”‚
â”‚       â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â–¶    â”‚
â”‚                          ALLELE FREQUENCY                                       â”‚
â”‚                      Rare â—„â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â–º Common                          â”‚
â”‚                                                                                 â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
```

### 5.2 Major Epilepsy Genes

```
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚                         MAJOR EPILEPSY GENES                                    â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚                                                                                 â”‚
â”‚  ğŸ”´ SODIUM CHANNELS                                                            â”‚
â”‚  â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•             â”‚
â”‚  â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”¬â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¬â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¬â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”          â”‚
â”‚  â”‚ Gene   â”‚ Channel  â”‚ Phenotype               â”‚ Prevalence        â”‚          â”‚
â”‚  â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤          â”‚
â”‚  â”‚ SCN1A  â”‚ Nav1.1   â”‚ Dravet, GEFS+           â”‚ 1:12,200 births   â”‚          â”‚
â”‚  â”‚ SCN2A  â”‚ Nav1.2   â”‚ Early DEE, BFNIS        â”‚ --                â”‚          â”‚
â”‚  â”‚ SCN8A  â”‚ Nav1.6   â”‚ Early DEE               â”‚ --                â”‚          â”‚
â”‚  â””â”€â”€â”€â”€â”€â”€â”€â”€â”´â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”´â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”´â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜          â”‚
â”‚                                                                                 â”‚
â”‚  ğŸ”µ POTASSIUM CHANNELS                                                         â”‚
â”‚  â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•             â”‚
â”‚  â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”¬â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¬â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¬â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”          â”‚
â”‚  â”‚ Gene   â”‚ Channel  â”‚ Phenotype               â”‚ Prevalence        â”‚          â”‚
â”‚  â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤          â”‚
â”‚  â”‚ KCNQ2  â”‚ Kv7.2    â”‚ BFNE, KCNQ2-DEE         â”‚ 1:17,000 births   â”‚          â”‚
â”‚  â”‚ KCNT1  â”‚ KNa1.1   â”‚ EIMFS, ADNFLE           â”‚ --                â”‚          â”‚
â”‚  â”‚ KCNA2  â”‚ Kv1.2    â”‚ DEE, episodic ataxia    â”‚ --                â”‚          â”‚
â”‚  â””â”€â”€â”€â”€â”€â”€â”€â”€â”´â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”´â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”´â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜          â”‚
â”‚                                                                                 â”‚
â”‚  ğŸŸ¢ SYNAPTIC FUNCTION                                                          â”‚
â”‚  â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•             â”‚
â”‚  â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”¬â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¬â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”           â”‚
â”‚  â”‚ Gene   â”‚ Function          â”‚ Phenotype                         â”‚           â”‚
â”‚  â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤           â”‚
â”‚  â”‚ STXBP1 â”‚ Vesicle release   â”‚ Ohtahara, West, DEE               â”‚           â”‚
â”‚  â”‚ SYNGAP1â”‚ Synaptic plasticityâ”‚ ID + epilepsy                    â”‚           â”‚
â”‚  â”‚ CDKL5  â”‚ Kinase signaling  â”‚ CDKL5-DEE, atypical Rett          â”‚           â”‚
â”‚  â”‚ PCDH19 â”‚ Cell adhesion     â”‚ Clustering epilepsy (â™€)           â”‚           â”‚
â”‚  â””â”€â”€â”€â”€â”€â”€â”€â”€â”´â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”´â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜           â”‚
â”‚                                                                                 â”‚
â”‚  ğŸŸ¡ OTHER IMPORTANT GENES                                                      â”‚
â”‚  â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•             â”‚
â”‚  â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”¬â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¬â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”           â”‚
â”‚  â”‚ Gene   â”‚ Function          â”‚ Phenotype                         â”‚           â”‚
â”‚  â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤           â”‚
â”‚  â”‚ PRRT2  â”‚ Synaptic protein  â”‚ PKD, BFIE (1:9,970 - most common!)â”‚           â”‚
â”‚  â”‚ SLC2A1 â”‚ Glucose transport â”‚ GLUT1 deficiency (1:24,300)       â”‚           â”‚
â”‚  â”‚ TSC1/2 â”‚ mTOR pathway      â”‚ Tuberous sclerosis                â”‚           â”‚
â”‚  â”‚ DEPDC5 â”‚ mTOR pathway      â”‚ FFEVF, focal epilepsy             â”‚           â”‚
â”‚  â””â”€â”€â”€â”€â”€â”€â”€â”€â”´â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”´â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜           â”‚
â”‚                                                                                 â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
```

### 5.3 Developmental and Epileptic Encephalopathies (DEEs)

<div class="mermaid">
graph TD
    subgraph DEE["DEVELOPMENTAL & EPILEPTIC ENCEPHALOPATHIES (DEEs)"]
        A[Over 800 genes identified] --> B[Both epilepsy AND development affected]
        B --> C{Age of Onset}

        C -->|Neonatal| D[KCNQ2<br/>STXBP1<br/>SCN2A]
        C -->|Early Infantile| E[SCN1A<br/>CDKL5<br/>SCN8A]
        C -->|Infantile| F[ARX<br/>PCDH19<br/>SLC2A1]

        D --> G[Burst-Suppression Pattern]
        E --> H[Variable EEG]
        F --> I[Hypsarrhythmia possible]
    end

    style DEE fill:#fff5f5
    style D fill:#ffebee
    style E fill:#fff3e0
    style F fill:#e8f5e9
</div>

---

## 6. Medical Evaluation and Diagnostic Workup

### 6.1 First Seizure Evaluation Algorithm

<div class="mermaid">
flowchart TD
    A[ğŸš¨ FIRST UNPROVOKED SEIZURE] --> B{Child returned<br/>to baseline?}

    B -->|No| C[ğŸ”´ RED FLAGS]
    B -->|Yes| D{Risk factors<br/>present?}

    C --> C1[â€¢ Prolonged postictal >30min]
    C --> C2[â€¢ Focal neurological deficit]
    C --> C3[â€¢ Signs of elevated ICP]
    C --> C4[â€¢ History of trauma]
    C --> C5[â€¢ Age < 6 months]
    C --> C6[â€¢ Immunocompromised]

    C1 & C2 & C3 & C4 & C5 & C6 --> E[ğŸ¥ EMERGENT IMAGING<br/>CT â†’ MRI]

    D -->|Yes| F[Outpatient workup<br/>within 24-48h]
    D -->|No| G[Outpatient workup<br/>within 1-2 weeks]

    F --> H[ğŸ“‹ COMPLETE WORKUP]
    G --> H

    H --> H1[EEG - routine or sleep-deprived]
    H --> H2[MRI brain - epilepsy protocol]
    H --> H3[Labs if indicated]
    H --> H4[Consider genetics]

    style A fill:#ffcdd2
    style C fill:#ffebee
    style E fill:#ef5350,color:#fff
    style H fill:#e8f5e9
</div>

### 6.2 Diagnostic Workup Summary

```
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚                        FIRST SEIZURE WORKUP CHECKLIST                           â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚                                                                                 â”‚
â”‚  ğŸ“‹ IMMEDIATE (Emergency Department)                                            â”‚
â”‚  â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•                                          â”‚
â”‚  â–¡ Glucose (bedside + lab confirmation)                                         â”‚
â”‚  â–¡ Electrolytes (Na, Ca, Mg) if metabolic cause suspected                       â”‚
â”‚  â–¡ CBC if infection suspected                                                   â”‚
â”‚  â–¡ Toxicology screen if altered mental status                                   â”‚
â”‚  â–¡ CT head ONLY if red flags present                                           â”‚
â”‚                                                                                 â”‚
â”‚  ğŸ“‹ OUTPATIENT (Within 1-2 weeks)                                              â”‚
â”‚  â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•                                           â”‚
â”‚  â–¡ EEG (routine; sleep-deprived if initial normal)                             â”‚
â”‚  â–¡ MRI brain with epilepsy protocol                                            â”‚
â”‚  â–¡ Detailed developmental assessment                                            â”‚
â”‚                                                                                 â”‚
â”‚  ğŸ“‹ EXTENDED WORKUP (If indicated)                                             â”‚
â”‚  â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•                                           â”‚
â”‚  â–¡ Video-EEG monitoring                                                        â”‚
â”‚  â–¡ Genetic testing (panel, WES, WGS)                                           â”‚
â”‚  â–¡ Metabolic studies (lactate, amino acids, etc.)                              â”‚
â”‚  â–¡ LP with CSF studies                                                         â”‚
â”‚                                                                                 â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
```

### 6.3 When to Order Genetic Testing

<div class="mermaid">
flowchart LR
    A[Consider Genetic Testing] --> B{Clinical Features}

    B --> C[Early onset<br/>< 2 years]
    B --> D[Refractory to<br/>2+ ASMs]
    B --> E[Developmental<br/>regression]
    B --> F[Family history<br/>of epilepsy]
    B --> G[Dysmorphic<br/>features]
    B --> H[Specific EEG<br/>patterns]

    C & D & E & F & G & H --> I{Testing Strategy}

    I --> J[Chromosomal<br/>Microarray]
    I --> K[Epilepsy Gene<br/>Panel]
    I --> L[Whole Exome<br/>Sequencing]
    I --> M[Whole Genome<br/>Sequencing]

    J --> N[CNVs, Aneuploidy]
    K --> O[Known epilepsy genes]
    L --> P[Coding regions]
    M --> Q[Complete genome]

    style A fill:#e3f2fd
    style I fill:#fff3e0
</div>

### 6.4 Genetic Testing Algorithm

```
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚                    GENETIC TESTING DECISION PATHWAY                             â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚                                                                                 â”‚
â”‚                        STEP 1: Chromosomal Microarray                           â”‚
â”‚                        â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•                          â”‚
â”‚                                     â”‚                                           â”‚
â”‚                                     â–¼                                           â”‚
â”‚                    â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”                          â”‚
â”‚                    â”‚  Detects CNVs, deletions,      â”‚                          â”‚
â”‚                    â”‚  duplications, aneuploidy      â”‚                          â”‚
â”‚                    â”‚  Yield: ~5-10% in epilepsy     â”‚                          â”‚
â”‚                    â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜                          â”‚
â”‚                                     â”‚                                           â”‚
â”‚                              Normal â”‚                                           â”‚
â”‚                                     â–¼                                           â”‚
â”‚                        STEP 2: Gene Panel or WES                                â”‚
â”‚                        â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•                              â”‚
â”‚                                     â”‚                                           â”‚
â”‚              â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”´â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”                   â”‚
â”‚              â–¼                                              â–¼                   â”‚
â”‚  â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”              â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”        â”‚
â”‚  â”‚  SPECIFIC PHENOTYPE      â”‚              â”‚  UNKNOWN ETIOLOGY        â”‚        â”‚
â”‚  â”‚  â†’ Gene Panel            â”‚              â”‚  â†’ WES (Trio preferred)  â”‚        â”‚
â”‚  â”‚  â€¢ Faster turnaround     â”‚              â”‚  â€¢ Broader coverage      â”‚        â”‚
â”‚  â”‚  â€¢ Less VUS              â”‚              â”‚  â€¢ Higher yield (~30%)   â”‚        â”‚
â”‚  â”‚  â€¢ Lower cost            â”‚              â”‚  â€¢ More VUS              â”‚        â”‚
â”‚  â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜              â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜        â”‚
â”‚                                     â”‚                                           â”‚
â”‚                              Normal â”‚                                           â”‚
â”‚                                     â–¼                                           â”‚
â”‚                        STEP 3: Advanced Testing                                 â”‚
â”‚                        â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•                                 â”‚
â”‚                                     â”‚                                           â”‚
â”‚              â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”                   â”‚
â”‚              â–¼                      â–¼                      â–¼                   â”‚
â”‚  â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”    â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”    â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”            â”‚
â”‚  â”‚  WGS            â”‚    â”‚  RNA-seq        â”‚    â”‚  Functional     â”‚            â”‚
â”‚  â”‚  (non-coding)   â”‚    â”‚  (splicing)     â”‚    â”‚  Studies        â”‚            â”‚
â”‚  â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜    â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜    â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜            â”‚
â”‚                                                                                 â”‚
â”‚  â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•          â”‚
â”‚  ğŸ’¡ CLINICAL IMPACT: Finding the cause leads to management changes             â”‚
â”‚     in 36% of DEE patients!                                                    â”‚
â”‚  â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•          â”‚
â”‚                                                                                 â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
```

---

## 7. Physical Examination and Phenotyping

### 7.1 Systematic Phenotyping Approach

```
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚                    COMPREHENSIVE PHENOTYPING CHECKLIST                          â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚                                                                                 â”‚
â”‚  ğŸ“ GROWTH PARAMETERS                                                           â”‚
â”‚  â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•                                                         â”‚
â”‚  â–¡ Head circumference â†’ Plot on growth chart                                    â”‚
â”‚    â€¢ Microcephaly: < -2 SD (consider MECP2, FOXG1, genetic syndromes)          â”‚
â”‚    â€¢ Macrocephaly: > +2 SD (consider PTEN, megalencephaly syndromes)           â”‚
â”‚  â–¡ Height and weight â†’ Failure to thrive? Overgrowth?                          â”‚
â”‚  â–¡ Growth trajectory â†’ Crossing percentiles?                                    â”‚
â”‚                                                                                 â”‚
â”‚  ğŸ‘¤ CRANIOFACIAL EXAMINATION                                                   â”‚
â”‚  â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•                                                   â”‚
â”‚  â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¬â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”       â”‚
â”‚  â”‚ Region      â”‚ Features to Assess                                    â”‚       â”‚
â”‚  â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤       â”‚
â”‚  â”‚ Skull       â”‚ Shape, fontanelles (open/closed), sutures             â”‚       â”‚
â”‚  â”‚ Forehead    â”‚ Prominent? Sloping? Bossing?                          â”‚       â”‚
â”‚  â”‚ Eyes        â”‚ Spacing (hyper/hypotelorism), slant, epicanthus       â”‚       â”‚
â”‚  â”‚ Nose        â”‚ Bridge (depressed/prominent), tip, nares              â”‚       â”‚
â”‚  â”‚ Ears        â”‚ Position (low-set?), rotation, size, pits/tags        â”‚       â”‚
â”‚  â”‚ Mouth       â”‚ Philtrum length, lip thickness, palate                â”‚       â”‚
â”‚  â”‚ Chin        â”‚ Micro/retrognathia, prognathism                       â”‚       â”‚
â”‚  â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”´â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜       â”‚
â”‚                                                                                 â”‚
â”‚  ğŸ–ï¸ EXTREMITIES                                                                â”‚
â”‚  â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•                                                               â”‚
â”‚  â–¡ Digits: Count, syndactyly, polydactyly, clinodactyly                        â”‚
â”‚  â–¡ Palms: Single transverse crease, dermatoglyphics                            â”‚
â”‚  â–¡ Limbs: Proportions, contractures, tone                                      â”‚
â”‚                                                                                 â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
```

### 7.2 Neurocutaneous Markers

```
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚                        NEUROCUTANEOUS FINDINGS                                  â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚                                                                                 â”‚
â”‚  TUBEROUS SCLEROSIS COMPLEX (TSC1/TSC2)                                        â”‚
â”‚  â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•                                        â”‚
â”‚                                                                                 â”‚
â”‚  â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”   â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”   â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”           â”‚
â”‚  â”‚  ASH-LEAF SPOTS  â”‚   â”‚   SHAGREEN PATCH â”‚   â”‚  ANGIOFIBROMAS   â”‚           â”‚
â”‚  â”‚    (â•­â”€â”€â”€â”€â”€â”€â”€â•®)   â”‚   â”‚   â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”   â”‚   â”‚     â€¢ â€¢ â€¢        â”‚           â”‚
â”‚  â”‚    â”‚â–‘â–‘â–‘â–‘â–‘â–‘â–‘â”‚    â”‚   â”‚   â”‚â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â”‚   â”‚   â”‚    â€¢ â€¢ â€¢ â€¢      â”‚           â”‚
â”‚  â”‚    â”‚â–‘â–‘â–‘â–‘â–‘â–‘â–‘â”‚    â”‚   â”‚   â”‚â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â”‚   â”‚   â”‚     â€¢ â€¢ â€¢        â”‚           â”‚
â”‚  â”‚    â•°â”€â”€â”€â”€â”€â”€â”€â•¯     â”‚   â”‚   â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜   â”‚   â”‚   (nose, cheeks) â”‚           â”‚
â”‚  â”‚  Hypopigmented   â”‚   â”‚  Connective      â”‚   â”‚   Facial papules â”‚           â”‚
â”‚  â”‚  Wood's lamp (+) â”‚   â”‚  tissue nevus    â”‚   â”‚   appear age 3-5 â”‚           â”‚
â”‚  â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜   â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜   â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜           â”‚
â”‚                                                                                 â”‚
â”‚  NEUROFIBROMATOSIS TYPE 1 (NF1)                                                â”‚
â”‚  â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•                                               â”‚
â”‚                                                                                 â”‚
â”‚  â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”   â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”   â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”           â”‚
â”‚  â”‚ CAFÃ‰-AU-LAIT     â”‚   â”‚ AXILLARY/INGUINALâ”‚   â”‚ LISCH NODULES    â”‚           â”‚
â”‚  â”‚    â”Œâ”€â”€â”€â”€â”€â”€â”€â”     â”‚   â”‚    FRECKLING     â”‚   â”‚      â—‰           â”‚           â”‚
â”‚  â”‚    â”‚â–‘â–‘â–‘â–‘â–‘â–‘â–‘â”‚     â”‚   â”‚    Â· Â· Â· Â· Â·     â”‚   â”‚   (iris)         â”‚           â”‚
â”‚  â”‚    â””â”€â”€â”€â”€â”€â”€â”€â”˜     â”‚   â”‚    Â· Â· Â· Â· Â·     â”‚   â”‚                  â”‚           â”‚
â”‚  â”‚  â‰¥6 spots        â”‚   â”‚  Crowe sign      â”‚   â”‚  Slit lamp exam  â”‚           â”‚
â”‚  â”‚  >5mm prepubertalâ”‚   â”‚                  â”‚   â”‚                  â”‚           â”‚
â”‚  â”‚  >15mm adult     â”‚   â”‚                  â”‚   â”‚                  â”‚           â”‚
â”‚  â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜   â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜   â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜           â”‚
â”‚                                                                                 â”‚
â”‚  STURGE-WEBER SYNDROME                                                         â”‚
â”‚  â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•                                                         â”‚
â”‚                                                                                 â”‚
â”‚  â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”                                  â”‚
â”‚  â”‚      PORT-WINE STAIN (V1 distribution)   â”‚                                  â”‚
â”‚  â”‚                                          â”‚                                  â”‚
â”‚  â”‚           â•­â”€â”€â”€â”€â”€â”€â•®                       â”‚                                  â”‚
â”‚  â”‚          â•±â–“â–“â–“â–“â–“â–“â–“â–“â•²  â† Trigeminal V1    â”‚                                  â”‚
â”‚  â”‚         â”‚â–“â–“â–“â–“â–“â–“â–“â–“â–“â–“â”‚                     â”‚                                  â”‚
â”‚  â”‚         â”‚  â—‰    â—‰  â”‚                     â”‚                                  â”‚
â”‚  â”‚         â”‚    â–½     â”‚                     â”‚                                  â”‚
â”‚  â”‚         â”‚   â”€â”€â”€    â”‚                     â”‚                                  â”‚
â”‚  â”‚          â•²________â•±                      â”‚                                  â”‚
â”‚  â”‚                                          â”‚                                  â”‚
â”‚  â”‚  Associated with: leptomeningeal         â”‚                                  â”‚
â”‚  â”‚  angioma, glaucoma, seizures             â”‚                                  â”‚
â”‚  â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜                                  â”‚
â”‚                                                                                 â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
```

### 7.3 HPO and Standardized Terminology

```
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚                    PHENOTYPE DOCUMENTATION RESOURCES                            â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚                                                                                 â”‚
â”‚  ğŸŒ HUMAN PHENOTYPE ONTOLOGY (HPO)                                             â”‚
â”‚  â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•                                            â”‚
â”‚  Website: https://hpo.jax.org                                                  â”‚
â”‚                                                                                 â”‚
â”‚  â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”   â”‚
â”‚  â”‚                        HPO HIERARCHY EXAMPLE                            â”‚   â”‚
â”‚  â”‚                                                                         â”‚   â”‚
â”‚  â”‚  Abnormality of the nervous system (HP:0000707)                        â”‚   â”‚
â”‚  â”‚       â”‚                                                                 â”‚   â”‚
â”‚  â”‚       â”œâ”€â”€ Abnormal CNS morphology                                       â”‚   â”‚
â”‚  â”‚       â”‚       â”‚                                                         â”‚   â”‚
â”‚  â”‚       â”‚       â””â”€â”€ Cerebral cortical dysplasia                          â”‚   â”‚
â”‚  â”‚       â”‚                                                                 â”‚   â”‚
â”‚  â”‚       â””â”€â”€ Seizure (HP:0001250)                                         â”‚   â”‚
â”‚  â”‚               â”‚                                                         â”‚   â”‚
â”‚  â”‚               â”œâ”€â”€ Focal seizure                                         â”‚   â”‚
â”‚  â”‚               â”‚       â”œâ”€â”€ Focal aware seizure                          â”‚   â”‚
â”‚  â”‚               â”‚       â””â”€â”€ Focal impaired awareness seizure             â”‚   â”‚
â”‚  â”‚               â”‚                                                         â”‚   â”‚
â”‚  â”‚               â””â”€â”€ Generalized seizure                                   â”‚   â”‚
â”‚  â”‚                       â”œâ”€â”€ Absence seizure                              â”‚   â”‚
â”‚  â”‚                       â””â”€â”€ Tonic-clonic seizure                         â”‚   â”‚
â”‚  â”‚                                                                         â”‚   â”‚
â”‚  â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜   â”‚
â”‚                                                                                 â”‚
â”‚  ğŸ“š NIH ELEMENTS OF MORPHOLOGY                                                 â”‚
â”‚  â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•                                                â”‚
â”‚  Website: https://elementsofmorphology.nih.gov                                 â”‚
â”‚                                                                                 â”‚
â”‚  â€¢ Standardized definitions with photographs                                    â”‚
â”‚  â€¢ Anatomical terminology for dysmorphic features                              â”‚
â”‚  â€¢ Essential for consistent phenotype documentation                            â”‚
â”‚                                                                                 â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
```

---

## 8. Precision Medicine in Epilepsy

### 8.1 Gene-Specific Treatment Overview

<div class="mermaid">
flowchart TD
    subgraph PRECISION["ğŸ¯ PRECISION MEDICINE IN EPILEPSY"]
        A[Genetic Diagnosis] --> B{Gene Identified}

        B -->|SCN1A| C[ğŸ”´ DRAVET SYNDROME]
        B -->|KCNQ2| D[ğŸŸ¢ KCNQ2-EPILEPSY]
        B -->|SLC2A1| E[ğŸŸ¡ GLUT1 DEFICIENCY]
        B -->|TSC1/2| F[ğŸŸ£ TUBEROUS SCLEROSIS]

        C --> C1[âŒ AVOID Na+ blockers]
        C --> C2[âœ“ Valproate, Clobazam]
        C --> C3[âœ“ Stiripentol, CBD, Fenfluramine]

        D --> D1[âœ“ Na+ blockers EFFECTIVE]
        D --> D2[âœ“ Carbamazepine, Phenytoin]

        E --> E1[âœ“ KETOGENIC DIET]
        E --> E2[âš ï¸ Limited ASM efficacy]

        F --> F1[âœ“ mTOR inhibitors]
        F --> F2[âœ“ Everolimus, Sirolimus]
    end

    style PRECISION fill:#f5f5f5
    style C fill:#ffebee
    style D fill:#e8f5e9
    style E fill:#fff8e1
    style F fill:#f3e5f5
</div>

### 8.2 SCN1A/Dravet Syndrome - Critical Safety Information

```
â•”â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•—
â•‘                                                                               â•‘
â•‘   âš ï¸âš ï¸âš ï¸  DRAVET SYNDROME (SCN1A) - MEDICATION ALERT  âš ï¸âš ï¸âš ï¸                  â•‘
â•‘                                                                               â•‘
â• â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•£
â•‘                                                                               â•‘
â•‘   âŒ MEDICATIONS TO AVOID (Can worsen seizures & cause status epilepticus!)   â•‘
â•‘   â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•    â•‘
â•‘                                                                               â•‘
â•‘   SODIUM CHANNEL BLOCKERS:                                                    â•‘
â•‘   â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”    â•‘
â•‘   â”‚  â€¢ Phenytoin (Dilantin)       â€¢ Lacosamide (Vimpat)                â”‚    â•‘
â•‘   â”‚  â€¢ Fosphenytoin (Cerebyx)     â€¢ Rufinamide (Banzel)                â”‚    â•‘
â•‘   â”‚  â€¢ Carbamazepine (Tegretol)   â€¢ Eslicarbazepine                    â”‚    â•‘
â•‘   â”‚  â€¢ Oxcarbazepine (Trileptal)                                       â”‚    â•‘
â•‘   â”‚  â€¢ Lamotrigine (Lamictal)                                          â”‚    â•‘
â•‘   â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜    â•‘
â•‘                                                                               â•‘
â•‘   OTHER MEDICATIONS TO AVOID:                                                 â•‘
â•‘   â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”    â•‘
â•‘   â”‚  â€¢ Vigabatrin (Sabril)        â€¢ Pregabalin (Lyrica)                â”‚    â•‘
â•‘   â”‚  â€¢ Tiagabine (Gabitril)       â€¢ Gabapentin                         â”‚    â•‘
â•‘   â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜    â•‘
â•‘                                                                               â•‘
â•‘   âœ… RECOMMENDED TREATMENTS                                                   â•‘
â•‘   â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•                                                   â•‘
â•‘                                                                               â•‘
â•‘   FIRST-LINE:                                                                 â•‘
â•‘   â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”    â•‘
â•‘   â”‚  â€¢ Valproate (Depakote) + Clobazam (Onfi)                          â”‚    â•‘
â•‘   â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜    â•‘
â•‘                                                                               â•‘
â•‘   ADD-ON OPTIONS:                                                             â•‘
â•‘   â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”    â•‘
â•‘   â”‚  â€¢ Stiripentol (Diacomit)     â€¢ Topiramate                         â”‚    â•‘
â•‘   â”‚  â€¢ Cannabidiol (Epidiolex)    â€¢ Ketogenic diet                     â”‚    â•‘
â•‘   â”‚  â€¢ Fenfluramine (Fintepla)                                         â”‚    â•‘
â•‘   â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜    â•‘
â•‘                                                                               â•‘
â•‘   ğŸš¨ IN STATUS EPILEPTICUS:                                                  â•‘
â•‘   â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”    â•‘
â•‘   â”‚  âœ“ USE:   Benzodiazepines (Lorazepam, Midazolam, Diazepam)        â”‚    â•‘
â•‘   â”‚  âœ“ USE:   Valproate IV                                             â”‚    â•‘
â•‘   â”‚  âœ— AVOID: Phenytoin/Fosphenytoin (even in emergency!)             â”‚    â•‘
â•‘   â”‚  âœ— AVOID: Lacosamide                                               â”‚    â•‘
â•‘   â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜    â•‘
â•‘                                                                               â•‘
â•šâ•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•
```

### 8.3 Treatment Comparison: SCN1A vs KCNQ2

```
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚            OPPOSITE TREATMENT STRATEGIES: SCN1A vs KCNQ2                        â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚                                                                                 â”‚
â”‚                    SCN1A                          KCNQ2                         â”‚
â”‚              (Dravet Syndrome)              (KCNQ2 Epilepsy)                   â”‚
â”‚                                                                                 â”‚
â”‚   Mechanism:   Loss of Nav1.1          Mechanism:   Loss of Kv7.2              â”‚
â”‚                function in             (or Gain of function)                   â”‚
â”‚                inhibitory neurons                                               â”‚
â”‚                                                                                 â”‚
â”‚                     â”‚                              â”‚                            â”‚
â”‚                     â–¼                              â–¼                            â”‚
â”‚        â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”    â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”               â”‚
â”‚        â”‚    Na+ CHANNEL         â”‚    â”‚    Na+ CHANNEL         â”‚               â”‚
â”‚        â”‚    BLOCKERS            â”‚    â”‚    BLOCKERS            â”‚               â”‚
â”‚        â”‚                        â”‚    â”‚                        â”‚               â”‚
â”‚        â”‚   âŒ CONTRAINDICATED   â”‚    â”‚   âœ… FIRST-LINE        â”‚               â”‚
â”‚        â”‚                        â”‚    â”‚                        â”‚               â”‚
â”‚        â”‚   â€¢ Worsen seizures    â”‚    â”‚   â€¢ Often effective    â”‚               â”‚
â”‚        â”‚   â€¢ Can cause SE       â”‚    â”‚   â€¢ CBZ, OXC, PHT      â”‚               â”‚
â”‚        â”‚   â€¢ May be fatal       â”‚    â”‚   â€¢ Early response     â”‚               â”‚
â”‚        â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜    â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜               â”‚
â”‚                                                                                 â”‚
â”‚   â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â” â”‚
â”‚   â”‚  ğŸ’¡ CLINICAL PEARL: Genetic diagnosis BEFORE medication selection       â”‚ â”‚
â”‚   â”‚     can prevent harm and improve outcomes!                               â”‚ â”‚
â”‚   â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜ â”‚
â”‚                                                                                 â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
```

### 8.4 Emerging Therapies

```
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚                         EMERGING PRECISION THERAPIES                            â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚                                                                                 â”‚
â”‚  ğŸ§¬ ANTISENSE OLIGONUCLEOTIDES (ASO)                                           â”‚
â”‚  â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•                                           â”‚
â”‚  â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”   â”‚
â”‚  â”‚  Target: SCN1A (Dravet syndrome)                                        â”‚   â”‚
â”‚  â”‚  Mechanism: Upregulate SCN1A expression via TANGO approach              â”‚   â”‚
â”‚  â”‚  Status: Phase 3 clinical trials (Zorevunersen)                         â”‚   â”‚
â”‚  â”‚                                                                         â”‚   â”‚
â”‚  â”‚     Normal mRNA  â†’  [ASO blocks inhibitor]  â†’  â†‘ Nav1.1 protein        â”‚   â”‚
â”‚  â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜   â”‚
â”‚                                                                                 â”‚
â”‚  ğŸ¦  GENE THERAPY                                                               â”‚
â”‚  â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•                                                               â”‚
â”‚  â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”   â”‚
â”‚  â”‚  ETX101 (Encoded Therapeutics)                                          â”‚   â”‚
â”‚  â”‚  â€¢ AAV-delivered gene therapy for Dravet                                â”‚   â”‚
â”‚  â”‚  â€¢ Targets SCN1A expression in inhibitory neurons                       â”‚   â”‚
â”‚  â”‚  â€¢ Status: Phase 1/2 trials                                             â”‚   â”‚
â”‚  â”‚                                                                         â”‚   â”‚
â”‚  â”‚     AAV vector  â†’  [Delivery to neurons]  â†’  â†‘ SCN1A expression        â”‚   â”‚
â”‚  â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜   â”‚
â”‚                                                                                 â”‚
â”‚  âœ‚ï¸ GENE EDITING (CRISPR)                                                      â”‚
â”‚  â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•                                                      â”‚
â”‚  â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”   â”‚
â”‚  â”‚  Approach: dCas9-mediated promoter activation                           â”‚   â”‚
â”‚  â”‚  Target: Upregulate SCN1A expression                                    â”‚   â”‚
â”‚  â”‚  Status: Preclinical (mouse models successful)                          â”‚   â”‚
â”‚  â”‚                                                                         â”‚   â”‚
â”‚  â”‚  Challenges:                                                            â”‚   â”‚
â”‚  â”‚  â€¢ CNS delivery                                                         â”‚   â”‚
â”‚  â”‚  â€¢ Potential immune response to Cas9                                    â”‚   â”‚
â”‚  â”‚  â€¢ Off-target effects                                                   â”‚   â”‚
â”‚  â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜   â”‚
â”‚                                                                                 â”‚
â”‚  ğŸ’Š SMALL MOLECULE MODULATORS                                                  â”‚
â”‚  â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•                                                  â”‚
â”‚  â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”   â”‚
â”‚  â”‚  â€¢ Ezogabine (KCNQ2): Compassionate use                                 â”‚   â”‚
â”‚  â”‚  â€¢ Quinidine (KCNT1): Limited efficacy                                  â”‚   â”‚
â”‚  â”‚  â€¢ mTOR inhibitors (TSC): FDA approved (Everolimus)                     â”‚   â”‚
â”‚  â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜   â”‚
â”‚                                                                                 â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
```

---

## 9. Clinical Pearls and Pitfalls

### 9.1 Diagnostic Pearls

```
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚                           ğŸ’ DIAGNOSTIC PEARLS                                  â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚                                                                                 â”‚
â”‚  ğŸ”¥ "Fever + prolonged seizure in infant â†’ Think SCN1A"                        â”‚
â”‚  â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€                         â”‚
â”‚  First febrile seizure that is prolonged (>15 min), hemiclonic,                â”‚
â”‚  or followed by more seizures = HIGH suspicion for Dravet                      â”‚
â”‚  â†’ Order SCN1A testing early, AVOID sodium channel blockers                    â”‚
â”‚                                                                                 â”‚
â”‚  ğŸ“Š "Burst-suppression in neonate â†’ Think STXBP1, KCNQ2, SCN2A"               â”‚
â”‚  â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€                â”‚
â”‚  Severe early-onset DEE with burst-suppression pattern                         â”‚
â”‚  â†’ Urgent genetic panel, consider sodium channel blockers for KCNQ2            â”‚
â”‚                                                                                 â”‚
â”‚  â™€ï¸ "Seizures only in females + variable severity â†’ Think PCDH19"              â”‚
â”‚  â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€              â”‚
â”‚  Seizure clusters, often fever-related, males are unaffected carriers          â”‚
â”‚  â†’ X-linked inheritance with cellular mosaicism                                â”‚
â”‚                                                                                 â”‚
â”‚  ğŸ¬ "Low CSF glucose + normal blood glucose â†’ Think GLUT1"                     â”‚
â”‚  â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€                     â”‚
â”‚  CSF:blood glucose ratio <0.4, movement disorder, developmental delay          â”‚
â”‚  â†’ SLC2A1 testing, ketogenic diet is treatment of choice                       â”‚
â”‚                                                                                 â”‚
â”‚  ğŸŒ™ "Seizures only from sleep + centrotemporal spikes â†’ Think SLECTS"          â”‚
â”‚  â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€          â”‚
â”‚  Benign rolandic epilepsy, speech arrest, drooling                             â”‚
â”‚  â†’ Usually no imaging needed, excellent prognosis, often no treatment          â”‚
â”‚                                                                                 â”‚
â”‚  ğŸ‘€ "Staring spells + 3Hz spike-wave + hyperventilation trigger â†’ Think CAE"   â”‚
â”‚  â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€       â”‚
â”‚  Brief (<30 sec) absence seizures, multiple per day                            â”‚
â”‚  â†’ First-line: Ethosuximide or Valproate, 70% remission by adolescence        â”‚
â”‚                                                                                 â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
```

### 9.2 Common Pitfalls to Avoid

```
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚                          âš ï¸ COMMON PITFALLS                                     â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚                                                                                 â”‚
â”‚  âŒ PITFALL 1: Starting sodium channel blocker without genetic diagnosis        â”‚
â”‚  â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•           â”‚
â”‚                                                                                 â”‚
â”‚     Scenario: Infant with febrile seizures started on phenytoin                â”‚
â”‚               Later diagnosed with Dravet syndrome                              â”‚
â”‚                                                                                 â”‚
â”‚     Result:   Seizure worsening, status epilepticus                            â”‚
â”‚                                                                                 â”‚
â”‚     Prevention: â€¢ Consider genetics early in refractory infant epilepsy        â”‚
â”‚                 â€¢ Use valproate/clobazam as first-line if Dravet suspected     â”‚
â”‚                                                                                 â”‚
â”‚  âŒ PITFALL 2: Misinterpreting normal EEG variants as epileptiform             â”‚
â”‚  â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•           â”‚
â”‚                                                                                 â”‚
â”‚     Common mistakes:                                                            â”‚
â”‚     â€¢ Posterior slow waves of youth â†’ Called "occipital spikes"                â”‚
â”‚     â€¢ Hypnagogic hypersynchrony â†’ Called "generalized slowing"                 â”‚
â”‚     â€¢ Wicket spikes â†’ Called "temporal sharp waves"                            â”‚
â”‚                                                                                 â”‚
â”‚     Prevention: â€¢ Know age-appropriate normal variants                         â”‚
â”‚                 â€¢ Correlate with clinical history                              â”‚
â”‚                                                                                 â”‚
â”‚  âŒ PITFALL 3: Skipping developmental history                                  â”‚
â”‚  â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•           â”‚
â”‚                                                                                 â”‚
â”‚     Missed: Developmental regression preceding seizure onset                    â”‚
â”‚             (Key feature of DEE, metabolic disorders)                           â”‚
â”‚                                                                                 â”‚
â”‚     Prevention: â€¢ Always document developmental milestones                     â”‚
â”‚                 â€¢ Ask about skill loss, plateau                                â”‚
â”‚                                                                                 â”‚
â”‚  âŒ PITFALL 4: Inadequate family history                                       â”‚
â”‚  â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•           â”‚
â”‚                                                                                 â”‚
â”‚     Missed: â€¢ Autosomal dominant epilepsy syndromes                            â”‚
â”‚             â€¢ Consanguinity (recessive disorders)                               â”‚
â”‚             â€¢ Febrile seizures in relatives (GEFS+, Dravet)                    â”‚
â”‚                                                                                 â”‚
â”‚     Prevention: â€¢ Three-generation pedigree                                    â”‚
â”‚                 â€¢ Ask about seizures, developmental delay, early deaths        â”‚
â”‚                                                                                 â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
```

---

## 10. Summary: Approach to Pediatric Neurologic Diseases

### 10.1 Etiology Framework

```
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚                    ETIOLOGY OF PEDIATRIC NEUROLOGIC DISEASES                    â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚                                                                                 â”‚
â”‚                            â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”                                  â”‚
â”‚                            â”‚   PEDIATRIC     â”‚                                  â”‚
â”‚                            â”‚   NEUROLOGIC    â”‚                                  â”‚
â”‚                            â”‚   DISEASES      â”‚                                  â”‚
â”‚                            â””â”€â”€â”€â”€â”€â”€â”€â”€â”¬â”€â”€â”€â”€â”€â”€â”€â”€â”˜                                  â”‚
â”‚                                     â”‚                                           â”‚
â”‚         â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¬â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¬â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”              â”‚
â”‚         â–¼               â–¼           â–¼           â–¼               â–¼              â”‚
â”‚   â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”   â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â” â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â” â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”  â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”         â”‚
â”‚   â”‚  ğŸ§¬      â”‚   â”‚  âš—ï¸      â”‚ â”‚  ğŸ¦       â”‚ â”‚  ğŸŒ      â”‚  â”‚  ğŸ¥      â”‚         â”‚
â”‚   â”‚ GENETIC  â”‚   â”‚METABOLIC â”‚ â”‚INFECTIOUSâ”‚ â”‚ENVIRON-  â”‚  â”‚STRUCTURALâ”‚         â”‚
â”‚   â”‚          â”‚   â”‚          â”‚ â”‚          â”‚ â”‚ MENTAL   â”‚  â”‚          â”‚         â”‚
â”‚   â””â”€â”€â”€â”€â”¬â”€â”€â”€â”€â”€â”˜   â””â”€â”€â”€â”€â”¬â”€â”€â”€â”€â”€â”˜ â””â”€â”€â”€â”€â”¬â”€â”€â”€â”€â”€â”˜ â””â”€â”€â”€â”€â”¬â”€â”€â”€â”€â”€â”˜  â””â”€â”€â”€â”€â”¬â”€â”€â”€â”€â”€â”˜         â”‚
â”‚        â”‚              â”‚            â”‚            â”‚              â”‚               â”‚
â”‚        â–¼              â–¼            â–¼            â–¼              â–¼               â”‚
â”‚   â€¢ Monogenic    â€¢ IEM       â€¢ Meningitis  â€¢ HIE         â€¢ Malformations     â”‚
â”‚   â€¢ Chromosomal  â€¢ Mito      â€¢ Encephalitisâ€¢ Toxins      â€¢ Tumors            â”‚
â”‚   â€¢ Complex      â€¢ Storage   â€¢ TORCH       â€¢ Trauma      â€¢ Vascular          â”‚
â”‚                                                                                 â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
```

### 10.2 Clinical Approach Summary

<div class="mermaid">
flowchart TD
    A[ğŸ‘¶ Child with Neurological Concern] --> B[ğŸ“‹ COMPREHENSIVE HISTORY]

    B --> B1[Prenatal: exposures, infections]
    B --> B2[Perinatal: complications, APGAR]
    B --> B3[Development: milestones, regression]
    B --> B4[Seizure: detailed semiology]
    B --> B5[Family: 3-generation pedigree]

    B1 & B2 & B3 & B4 & B5 --> C[ğŸ” PHYSICAL EXAMINATION]

    C --> C1[Growth parameters]
    C --> C2[Dysmorphic features]
    C --> C3[Skin: neurocutaneous]
    C --> C4[Neurological exam]
    C --> C5[Developmental assessment]

    C1 & C2 & C3 & C4 & C5 --> D[ğŸ§ª INVESTIGATIONS]

    D --> D1[EEG]
    D --> D2[MRI brain]
    D --> D3[Genetic testing]
    D --> D4[Metabolic workup]

    D1 & D2 & D3 & D4 --> E[ğŸ“Š DIAGNOSIS]

    E --> E1[Classify seizure type]
    E --> E2[Determine epilepsy type]
    E --> E3[Identify syndrome]
    E --> E4[Find etiology]

    E1 & E2 & E3 & E4 --> F[ğŸ’Š MANAGEMENT]

    F --> F1[Gene-specific treatment]
    F --> F2[Avoid contraindicated drugs]
    F --> F3[Consider non-pharmacologic]
    F --> F4[Genetic counseling]

    style A fill:#e3f2fd
    style B fill:#fff3e0
    style C fill:#e8f5e9
    style D fill:#fce4ec
    style E fill:#f3e5f5
    style F fill:#e0f7fa
</div>

---

## 11. Learning Objectives and Self-Assessment

### 11.1 Learning Objectives Checklist

After completing this lecture, students should be able to:

| # | Objective | Self-Check |
|---|-----------|------------|
| 1 | Define seizure, epilepsy, and status epilepticus | â–¡ |
| 2 | Apply the ILAE 2017/2022 classification system | â–¡ |
| 3 | Interpret age-appropriate EEG findings | â–¡ |
| 4 | List major epilepsy genes and their phenotypes | â–¡ |
| 5 | Outline the diagnostic workup for first seizure | â–¡ |
| 6 | Perform systematic phenotyping using HPO terminology | â–¡ |
| 7 | Recognize when genetic testing is indicated | â–¡ |
| 8 | Identify gene-specific treatment considerations | â–¡ |
| 9 | Avoid medications contraindicated in specific genetic epilepsies | â–¡ |
| 10 | Counsel families on epilepsy prognosis and management | â–¡ |

### 11.2 Self-Assessment Questions

<details>
<summary><b>Question 1:</b> A 6-month-old presents with recurrent prolonged seizures triggered by fever. Genetic testing reveals an SCN1A pathogenic variant. Which medication should be AVOIDED?</summary>

**Answer**:
Sodium channel blockers should be **AVOIDED**:
- Phenytoin/Fosphenytoin
- Carbamazepine
- Oxcarbazepine
- Lamotrigine
- Lacosamide

These drugs block sodium channels and can worsen seizures in Dravet syndrome because SCN1A mutations already cause loss of Nav1.1 function in inhibitory neurons.

**First-line treatment**: Valproate + Clobazam
</details>

<details>
<summary><b>Question 2:</b> What is the expected posterior dominant rhythm frequency for a healthy 3-year-old?</summary>

**Answer**:
**7-8 Hz**

PDR maturation follows this pattern:
- 6 months: 4-5 Hz
- 1 year: 5-6 Hz
- 2 years: 6-7 Hz
- **3 years: 7-8 Hz**
- 8 years: 8-9 Hz
- 10 years: 9-10 Hz (adult-like)

Clinical pearl: PDR should be approximately [age in years + 2-3] Hz
</details>

<details>
<summary><b>Question 3:</b> A neonate presents with tonic seizures on day 3 of life. EEG shows burst-suppression. Which genes should be prioritized for testing?</summary>

**Answer**:
Priority genes for neonatal-onset DEE with burst-suppression:
1. **STXBP1** - Most common cause of Ohtahara syndrome
2. **KCNQ2** - Early neonatal onset, may respond to sodium channel blockers
3. **SCN2A** - Variable phenotype
4. **KCNT1** - EIMFS
5. **ARX** (in males) - X-linked

Consider urgent epilepsy gene panel or rapid trio whole exome sequencing.
</details>

<details>
<summary><b>Question 4:</b> When is emergent neuroimaging indicated after a first unprovoked seizure?</summary>

**Answer**:
Emergent imaging (CT initially, MRI when stable) is indicated for:

**RED FLAGS:**
- Prolonged postictal state (>30 minutes)
- Persistent focal neurological deficit
- Signs of elevated intracranial pressure
- History of significant head trauma
- Immunocompromised state
- Concern for child abuse
- Age < 6 months with symptomatic seizure
- New focal findings on examination

**NOT required if:**
- Child returned to baseline
- Non-focal examination
- Recognized benign epilepsy syndrome
- Simple febrile seizure
</details>

<details>
<summary><b>Question 5:</b> What is the first-line treatment for KCNQ2-related epilepsy, and why does this differ from Dravet syndrome?</summary>

**Answer**:
**KCNQ2 first-line**: Sodium channel blockers (Carbamazepine, Oxcarbazepine, Phenytoin)

**Why the opposite of Dravet?**

| Feature | SCN1A (Dravet) | KCNQ2 |
|---------|---------------|-------|
| Affected channel | Nav1.1 (sodium) | Kv7.2 (potassium) |
| Mutation effect | Loss of function in inhibitory neurons | Loss or gain of function |
| Na+ blockers | Worsen seizures | Often effective |
| Mechanism | Further reduces inhibitory neuron function | Different pathophysiology |

This illustrates why genetic diagnosis BEFORE medication selection is critical for precision medicine in epilepsy.
</details>

<details>
<summary><b>Question 6:</b> A 5-year-old girl has absence seizures provoked by hyperventilation, with 3 Hz generalized spike-wave on EEG. What is the diagnosis and prognosis?</summary>

**Answer**:
**Diagnosis**: Childhood Absence Epilepsy (CAE)

**Key features**:
- Age 4-8 years
- Brief (5-15 second) staring spells
- Multiple episodes daily
- Triggered by hyperventilation
- 3 Hz generalized spike-wave

**Prognosis**: GOOD
- ~70% achieve remission by adolescence
- Some develop JME or GTC seizures

**Treatment**:
- First-line: Ethosuximide (absence only) or Valproate (if GTC risk)
- Avoid: Carbamazepine, Phenytoin (can worsen absence)
</details>

---

## 12. References and Further Reading

### Key References

1. **ILAE Classification**
   - [ILAE Definition & Classification Portal](https://www.ilae.org/guidelines/definition-and-classification)
   - Specchio N, et al. *Epilepsia* 2022 - Childhood epilepsy syndromes
   - [Updated Classification of Epileptic Seizures (2025)](https://onlinelibrary.wiley.com/doi/10.1111/epi.18338)

2. **Pediatric EEG**
   - [NCBI Bookshelf: Developmental EEG](https://www.ncbi.nlm.nih.gov/books/NBK390356/)
   - [LearningEEG.com Pediatric Resources](https://www.learningeeg.com/pediatric)

3. **Genetic Epilepsies**
   - McTague A, et al. *Lancet Neurology* 2016 - Genetic landscape of epileptic encephalopathies
   - [Precision medicine in KCNQ2 epilepsy](https://jtggjournal.com/article/view/3566)

4. **Phenotyping Resources**
   - [Human Phenotype Ontology (HPO)](https://hpo.jax.org/)
   - [NIH Elements of Morphology](https://elementsofmorphology.nih.gov)

5. **Clinical Guidelines**
   - [CHOP Unprovoked Seizure Clinical Pathway](https://www.chop.edu/clinical-pathway/unprovoked-seizure-clinical-pathway)
   - [Dravet Syndrome Treatment Guide](https://pmc.ncbi.nlm.nih.gov/articles/PMC8927048/)

### Online Resources

| Resource | URL | Description |
|----------|-----|-------------|
| ILAE | [ilae.org](https://ilae.org) | Classification, guidelines |
| HPO | [hpo.jax.org](https://hpo.jax.org) | Phenotype terminology |
| OMIM | [omim.org](https://omim.org) | Gene-disease relationships |
| GeneReviews | [ncbi.nlm.nih.gov/books/NBK1116/](https://ncbi.nlm.nih.gov/books/NBK1116/) | Clinical genetic summaries |
| ClinVar | [ncbi.nlm.nih.gov/clinvar/](https://ncbi.nlm.nih.gov/clinvar/) | Variant interpretation |

### Suggested Textbooks

- Swaiman's Pediatric Neurology (6th edition)
- Pediatric Epilepsy (Pellock, Nordli, Sankar, Wheless)
- Atlas of Pediatric EEG (Blume, Kaibara, Young)

---

## Version History

| Version | Date | Changes |
|---------|------|---------|
| 1.0 | 2023-10-23 | Initial student lecture |
| 2.0 | 2025-01 | Comprehensive update: ILAE 2022/2025, genetic content, precision medicine |
| 2.1 | 2025-01 | Enhanced visual materials: diagrams, flowcharts, Mermaid charts |

---

## Acknowledgments

This lecture material is prepared for medical student education by YK Shim, Division of Pediatric Neurology, Department of Pediatrics, Korea University College of Medicine.

---

*This document is intended for educational purposes. Clinical decisions should be based on individual patient assessment and current guidelines.*

**License**: [CC BY-NC-SA 4.0](https://creativecommons.org/licenses/by-nc-sa/4.0/)

---
